The GLP-1 Receptor Agonist by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The GLP-1 Receptor Agonist Market:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report
According to The Business Research Company’s GLP-1 Receptor Agonist, The glp-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.1 billion in 2023 to $13.74 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rising diabetes prevalence, clinical efficacy, patient awareness and acceptance, global health initiatives, patient preference for injectable therapies.
The glp-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $16.82 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing emphasis on lifestyle management, growing personalized medicine approaches, expanding indications, development of next-generation products, integration into combination therapies.. Major trends in the forecast period include introduction of oral formulations, focus on combination therapies, strategic partnerships and collaborations, reimbursement policies and access, patient-centric approaches.
The rising prevalence of diabetes is expected to propel the GLP-1 receptor agonist market going forward. Diabetes is a chronic illness that develops when the pancreas either produces insufficient amounts of insulin or when the body cannot properly utilize the insulin that it does. High blood sugar is a symptom of the metabolic disorder diabetes mellitus. GLP-1 receptor agonist is used in diabetes to stimulate the body to produce more insulin, which helps to lower blood sugar levels, so the rising prevalence of diabetes will propel the market growth. For instance, in December 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of over 230 national diabetes associations, the global population living with diabetes is approximately 537 million adults and further it is projected to rise to 643 million by 2030. Therefore, the rising prevalence of diabetes is driving the GLP-1 receptor agonist market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp
The glp-1 receptor agonist market covered in this report is segmented –
1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users
Top Major Players:
- Novo Nordisk A/S
- Sanofi SA
- Eli Lilly and Company
- AstraZeneca Inc.
- Boehringer Ingelheim International GmbH
North America was the largest region in the GLP-1 receptor agonist market in 2023.
Product innovations are a key trend gaining popularity in the GLP-1 receptor agonist market. Major companies operating in the GLP-1 receptor agonist market are focused on developing innovative solutions to strengthen their position. For instance, in May 2022, Eli Lilly and Company, a US-based pharmaceutical company that creates medicines that make life better for people, launched the FDA-approved new Mounjaro, a GIP and GLP-1 receptor agonist. It is specially designed using a single molecule that turns on the body’s receptors for the incretin hormones GIP and GLP-1. It is available as a pen auto-injector with a pre-attached, hidden needle that patients do not need to handle or see, and it comes in 6 doses.
The glp-1 receptor agonist market report table of contents includes:
1. Executive Summary
2. GLP-1 Receptor Agonist Market Characteristics
3. Global GLP-1 Receptor Agonist Market Trends And Strategies
4. GLP-1 Receptor Agonist Market Macro Economic Scenario
5. Global GLP-1 Receptor Agonist Market Size and Growth
…….
26. Global GLP-1 Receptor Agonist Market Competitive Benchmarking
27. Global GLP-1 Receptor Agonist Market Competitive Dashboard
28. Key Mergers and Acquisitions In GLP-1 Receptor Agonist Market
29. GLP-1 Receptor Agonist Market Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
